Evidence map›Paper›PMID 40569513›Full record

ArticleDigestive diseases and sciences2025

Brewing a Cure: Engineering Yeast to Reduce Inflammation-Driven Tumors.

Declan F McCole

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Declan F McColeDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, CA, 92115, USA. declan.mccole@ucr.edu.

Funding

A NOVEL ROLE FOR PTPN2 IN INTESTINAL EPITHELIAL BARRIER REGULATIONR01DK091281 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Declan McCole · 2012 to 2026
$5.5M
Tyrosine Phosphatase Regulation of Mucosal Macrophage-Epithelial Cell Cross-talkR01AI153314 · NIAID · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI MCCOLE, DECLAN · 2020 to 2024
$2.5M
Targeted Identification of IBD Risk Gene Variant Impact on Immune-Epithelial Crosstalk and Intestinal Barrier FunctionR01DK138456 · NIDDK · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI Declan McCole · 2024 to 2026
$1.3M
Mechanistic Characterization of the IBD Risk Gene, PTPN2, as a Novel Susceptibility Marker for Increased SARS-CoV-2 InfectionR01DK130373 · NIDDK · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI MCCOLE, DECLAN · 2021 to 2023
$1.1M
National Institute of Allergy and Infectious Diseases 1R01AI153314NIAID NIH HHS R01 AI153314NIDDK NIH HHS 2R01DK091281NIDDK NIH HHS R01 DK091281NIDDK NIH HHS R01 DK130373NIDDK NIH HHS R01 DK138456
6 · The paper itself

Abstract

Culpepper et al. developed a novel bioengineered yeast-Saccharomyces boulardii-designed to specifically target exposed fibronectin in inflamed intestinal tissues and release anti-TNF nanobodies with the goal of reducing inflammation-driven tumorigenesis in a mouse model of colorectal adenocarcinoma.

Indexed as

AdenocarcinomaColorectal NeoplasmsSaccharomyces boulardiiAnimalsFibronectinsHumansInflammationMiceFibronectinsApc Min miceColorectal cancerFibronectinNanobodiesS. boulardiiTNF-α

Identifiers

PMID40569513
PMCPMC12771477

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.